Anna Tenditnaya

Anna Tenditnaya

Auto-generated profile, based on publicly available information

Anna Tenditnaya

Helmholtz Zentrum Mnchen, Institute of Biological and Medical Imaging, Neuherberg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2024 in IEEE Transactions on Medical Imaging
Verified
Journal Article
Open access
ATAnna Tenditnaya
Anna Tenditnaya
RGRuben Yannick Gabriels
Ruben Yannick Gabriels
WHWouter Hooghiemstra
Wouter Hooghiemstra
UKUwe Klemm
Uwe Klemm
WNWouter B. Nagengast
Wouter B. Nagengast
DGDimitris Gorpas
Dimitris Gorpas
Fluorescence molecular endoscopy (FME) is emerging as a “red-flag” technique with potential to deliver earlier, faster, and more personalized detection of disease in the gastrointestinal tract, including cancer, and to gain insights into novel drug distribution, dose finding, and response prediction. However, to date, the performance of FME systems is assessed mainly by endoscopists during a procedure, leading to arbitrary, potentially biased, and heavily subjective assessment. This approach significantly affects the repeatability of the procedures and the interpretation or comparison of the acquired data, representing a major bottleneck towards the clinical translation of the technology. Herein, we propose a robust methodology for FME performance assessment and quality control that is based on a novel multi-parametric rigid standard. This standard enables the characterization of an FME system’s sensitivity through a single acquisition, performance comparison of multiple systems, and, for the first time, quality control of a system as a function of time and number of usages. We show the photostability of the standard experimentally and demonstrate how it can be used to characterize the performance of an FME system. Moreover, we showcase how the standard can be employed for quality control of a system. In this study, we find that the use of composite fluorescence standards before endoscopic procedures can ensure that an FME system meets the performance criteria and that components prone to performance degradation are replaced in time, avoiding disruption of clinical endoscopy logistics. This will help overcome a major barrier for the translation of FME into the clinics.

21 February 2024 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SMSabrina Marcazzan
Sabrina Marcazzan
MCMarcos J. Braz Carvalho
Marcos J. Braz Carvalho
NNNghia T. Nguyen
Nghia T. Nguyen
JSJulia Strangmann
Julia Strangmann
JSJulia Slotta-Huspenina
Julia Slotta-Huspenina
SKSusanne Kossatz
Susanne Kossatz
Background: Esophageal cancer is one of the 10 most common cancers worldwide and its incidence is dramatically increasing. Despite some improvements, the current surveillance protocol with white light endoscopy and random untargeted biopsies collection (Seattle protocol) fails to diagnose dysplastic and cancerous lesions in up to 50% of patients. Therefore, new endoscopic imaging technologies in combination with tumor-specific molecular probes are needed to improve early detection. Herein, we investigated the use of the fluorescent Poly (ADP-ribose) Polymerase 1 (PARP1)-inhibitor PARPi-FL for early detection of dysplastic lesions in patient-derived organoids and transgenic mouse models, which closely mimic the transformation from non-malignant Barrett’s Esophagus (BE) to invasive esophageal adenocarcinoma (EAC). Methods: We determined PARP1 expression via immunohistochemistry (IHC) in human biospecimens and mouse tissues. We also assessed PARPi-FL uptake in patient- and mouse-derived organoids. Following intravenous injection of 75 nmol PARPi-FL/mouse in L2-IL1B (n = 4) and L2-IL1B/IL8Tg mice (n = 12), we conducted fluorescence molecular endoscopy (FME) and/or imaged whole excised stomachs to assess PARPi-FL accumulation in dysplastic lesions. L2-IL1B/IL8Tg mice (n = 3) and wild-type (WT) mice (n = 2) without PARPi-FL injection served as controls. The imaging results were validated by confocal microscopy and IHC of excised tissues. Results: IHC on patient and murine tissue revealed similar patterns of increasing PARP1 expression in presence of dysplasia and cancer. In human and murine organoids, PARPi-FL localized to PARP1-expressing epithelial cell nuclei after 10 min of incubation. Injection of PARPi-FL in transgenic mouse models of BE resulted in the successful detection of lesions via FME, with a mean target-to-background ratio > 2 independently from the disease stage. The localization of PARPi-FL in the lesions was confirmed by imaging of the excised stomachs and confocal microscopy. Without PARPi-FL injection, identification of lesions via FME in transgenic mice was not possible. Conclusion: PARPi-FL imaging is a promising approach for clinically needed improved detection of dysplastic and malignant EAC lesions in patients with BE. Since PARPi-FL is currently evaluated in a phase 2 clinical trial for oral cancer detection after topical application, clinical translation for early detection of dysplasia and EAC in BE patients via FME screening appears feasible.

8 November 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
YHYi-Jhih Huang
Yi-Jhih Huang
JRJonas Rieder
Jonas Rieder
KTKel Vin Tan
Kel Vin Tan
ATAnna Tenditnaya
Anna Tenditnaya
BVBorivoj Vojnovic
Borivoj Vojnovic
Kate VallisKate Vallis
Kate Vallis
Purpose: Esophageal cancer carries a poor prognosis with a 5-year overall survival of less than 20%. Barrett’s esophagus increases the risk of esophageal adenocarcinoma. The aim of this study was to investigate the ability of EMI-137, a mesenchymal–epithelial transition factor (c-MET)-targeting optical imaging tracer, to detect dysplasia in Barrett’s esophagus. Experimental Design: c-MET expression in human esophageal tissue was investigated using Gene Expression Omnibus datasets, tissue microarrays, and Barrett’s esophagus biopsies. EMI-137 was tested in a dual xenograft mouse model bearing OE33 (c-MET high expression) and FLO-1 (c-MET low expression) tumors. Fluorescence molecular endoscopy was performed in a mouse model of Barrett’s-like metaplasia and dysplasia (L2-IL1β). Tumors and organs of interest were evaluated through ex vivo fluorescence imaging. Results: MET mRNA expression analyses and c-MET immunostaining confirmed upregulation of c-MET in Barrett’s esophagus and esophageal adenocarcinoma compared with normal epithelium. There was strong accumulation of EMI-137 in OE33 xenografts 3 hours after injection, decreasing by more than 50% on coinjection of a 10-fold molar excess of unlabeled EMI-137. The target-to-background ratio at 3 hours after injection for OE33 and FLO-1 tumors was 10.08 and 1.42, respectively. Fluorescence molecular endoscopy of L2-IL1β mice showed uptake of EMI-137 in dysplastic lesions within Barrett’s esophagus with a target-to-background ratio of 1.9 in vivo and greater than 2 in ex vivo fluorescence imaging. Conclusions: EMI-137 accumulates in dysplastic lesions within Barrett’s esophagus and also in c-MET–positive esophageal adenocarcinoma. EMI-137 imaging has potential as a screening and surveillance tool for patients with Barrett’s esophagus and as a means to detecting dysplasia and esophageal adenocarcinoma.

6 January 2025
Verified
Other
Open access
PDF file
YHYi-Jhih Huang
Yi-Jhih Huang
JRJonas Rieder
Jonas Rieder
KTKel Vin Tan
Kel Vin Tan
ATAnna Tenditnaya
Anna Tenditnaya
BVBorivoj Vojnovic
Borivoj Vojnovic
Kate VallisKate Vallis
Kate Vallis
Supplementary Figure S4. Fluorescence molecular endoscopy study schema.

6 January 2025
Verified
Other
Open access
YHYi-Jhih Huang
Yi-Jhih Huang
JRJonas Rieder
Jonas Rieder
KTKel Vin Tan
Kel Vin Tan
ATAnna Tenditnaya
Anna Tenditnaya
BVBorivoj Vojnovic
Borivoj Vojnovic
Kate VallisKate Vallis
Kate Vallis
In vivo and ex vivo fluorescence imaging of EMI-137 in the dual xenograft model: A,In vivo fluorescence imaging 3 hours p.i. of EMI-137 showed a strong signal in the OE33 xenograft (right flank, white circle) but not in the FLO-1 xenograft (left flank, gray circle). B, Uptake of EMI-137 in OE33 tumors is effectively but not completely suppressed by coinjecting a 10-fold molar excess of unlabeled EMI-137 as a competitive blocking agent. C, Representative ex vivo tumor and organ panel of the dual xenograft model 3 hours p.i. of EMI-137 showing high uptake in OE33 tumor and kidney. D,Ex vivo tumor and organ panel taken from mice that received EMI-137 plus unlabeled EMI-137 coinjection as a blocking agent. E, Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137. F, Average radiant efficiency in tumors and organs 3 hours p.i. of EMI-137 plus a 10-fold molar excess of unlabeled EMI-137 showed more than 50% reduction of fluorescence in OE33 xenograft compared with E. n = 3 mice per group. ****, P < 0.0001. Avg, average; Max, maximum; Min, minimum; ns, not significant.

6 January 2025
Verified
Other
Open access
PDF file
YHYi-Jhih Huang
Yi-Jhih Huang
JRJonas Rieder
Jonas Rieder
KTKel Vin Tan
Kel Vin Tan
ATAnna Tenditnaya
Anna Tenditnaya
BVBorivoj Vojnovic
Borivoj Vojnovic
Kate VallisKate Vallis
Kate Vallis
Supplementary Figure S2. Establishment of a dual xenograft mouse model for testing EMI-137.